1: Lipponen A, Paananen J, Puhakka N, Pitkänen A. Analysis of Post-Traumatic Brain Injury Gene Expression Signature Reveals Tubulins, Nfe2l2, Nfkb, Cd44, and S100a4 as Treatment Targets. Sci Rep. 2016 Aug 17;6:31570. doi: 10.1038/srep31570. PMID: 27530814; PMCID: PMC4987651.
2: Haneda E, Higuchi M, Maeda J, Inaji M, Okauchi T, Ando K, Obayashi S, Nagai Y, Narazaki M, Ikehira H, Nakao R, Zhang MR, Suzuki K, Suzuki H, Suhara T. In vivo mapping of substance P receptors in brains of laboratory animals by high- resolution imaging systems. Synapse. 2007 Apr;61(4):205-15. doi: 10.1002/syn.20363. PMID: 17230554.
3: Campbell EA, Gentry C, Patel S, Kidd B, Cruwys S, Fox AJ, Urban L. Oral anti- hyperalgesic and anti-inflammatory activity of NK(1) receptor antagonists in models of inflammatory hyperalgesia of the guinea-pig. Pain. 2000 Sep;87(3):253-263. doi: 10.1016/S0304-3959(00)00288-8. PMID: 10963905.
4: Campbell EA, Gentry CT, Patel S, Panesar MS, Walpole CS, Urban L. Selective neurokinin-1 receptor antagonists are anti-hyperalgesic in a model of neuropathic pain in the guinea-pig. Neuroscience. 1998 Dec;87(3):527-32. doi: 10.1016/s0306-4522(98)00318-2. PMID: 9758219.
5: Rees H, Sluka KA, Urban L, Walpole CJ, Willis WD. The effects of SDZ NKT 343, a potent NK1 receptor antagonist, on cutaneous responses of primate spinothalamic tract neurones sensitized by intradermal capsaicin injection. Exp Brain Res. 1998 Aug;121(3):355-8. doi: 10.1007/s002210050468. PMID: 9746141.
6: Walpole C, Ko SY, Brown M, Beattie D, Campbell E, Dickenson F, Ewan S, Hughes GA, Lemaire M, Lerpiniere J, Patel S, Urban L. 2-Nitrophenylcarbamoyl-(S)-prolyl-(S)-3-(2-naphthyl)alanyl-N-benzyl-N - methylamide (SDZ NKT 343), a potent human NK1 tachykinin receptor antagonist with good oral analgesic activity in chronic pain models. J Med Chem. 1998 Aug 13;41(17):3159-73. doi: 10.1021/jm970499g. PMID: 9703462.
7: Walpole CS, Brown MC, James IF, Campbell EA, McIntyre P, Docherty R, Ko S, Hedley L, Ewan S, Buchheit KH, Urban LA. Comparative, general pharmacology of SDZ NKT 343, a novel, selective NK1 receptor antagonist. Br J Pharmacol. 1998 May;124(1):83-92. doi: 10.1038/sj.bjp.0701806. PMID: 9630347; PMCID: PMC1565365.